Skip to Content
MilliporeSigma
All Photos(4)

Documents

F3879

Sigma-Aldrich

Fibrinogen from human plasma

50-70% protein (≥80% of protein is clottable)

Synonym(s):

Factor I

Sign Into View Organizational & Contract Pricing


About This Item

CAS Number:
EC Number:
MDL number:
UNSPSC Code:
12352202
NACRES:
NA.61

biological source

human plasma

Quality Level

form

powder

quality

50-70% protein (≥80% of protein is clottable)

mol wt

α-chain 63.5 kDa
β-chain 56 kDa
γ chain 47 kDa (about 4% carbohydrate content)
soluble dimer 340 kDa

concentration

50-70% protein (biuret)

technique(s)

ELISA: suitable

solubility

0.9% NaCl: soluble 10 mg/mL

UniProt accession no.

storage temp.

−20°C

Gene Information

Looking for similar products? Visit Product Comparison Guide

General description

Fibrinogen, or Factor I, is a blood protein that is involved in clotting and is converted to fibrin by thrombin. Fibrinogen has an approximate molecular weight of 340 kDa

Application

Fibrinogen was used in the induction of release of TNF-like cytotoxic factor from murine macrophages. It was used for fabrication of fibrin scaffolds with controlled microscale architecture by a two-photon polymerization-micromolding technique.
Fibrinogen was also used in the development of a fibrinogen-specific sandwich enzyme-linked immunosorbent assay microarray assay for distinguishing between blood plasma and serum samples.
Fibrinogen from human plasma has been used-
  • for the production of fibrin hydrogels
  • for the preparation of fibrin-MSCs (mesenchymal stem cells)-cartilage constructs
  • for analyzing the protein repellent properties of PFDA-co-DEGDME (diethyleneglycol dimethyl ether) surface using Quartz crystal microbalance (QCM)

Biochem/physiol Actions

Fibrinogen is an acute phase protein that is part of the coagulation cascade of proteins. The end result of the cascade is the production of thrombin that converts fibrinogen to fibrin. Thrombin rapidly proteolyses fibrinogen, releasing fibrinopeptide A. The loss of this small peptide is not sufficient to make the resulting fibrin molecule insoluble, but it tends to form complexes with adjacent fibrin and fibrinogen molecules. Thrombin then cleaves a second peptide, fibrinopeptide B, from fibrin and the fibrin monomers formed then polymerize spontaneously to form an insoluble gel. The polymerized fibrin is held together by noncovalent and electrostatic forces and stabilized by the transamidating enzyme, factor XIIIa, that is produced by the action of thrombin on factor XIII. The insoluble fibrin aggregates (clots) and aggregated platelets then block the damaged blood vessel and prevent further bleeding. The amount of fibrinogen in the plasma can serve as a nonspecific indicator of whether or not an inflammatory process is present in the body. Fibrinogen from any mammalian source will be cleaved by thrombin from any mammalian source.

Specifications

Source material has tested negative for HIV and HBsAg.

Physical form

Lyophilized powder containing ~15% sodium citrate and ~25% sodium chloride.

Reconstitution

The optimal way to solubilize fibrinogen is to layer it on top of warm (37 ºC) saline, as fibrinogen will not dissolve in water. The saline concentration can be in the range of 0.85-0.9%. The fibrinogen-saline solution can be gently agitated, but it must not be vortexed. The fibrinogen will slowly dissolve to give a hazy solution. Fibrinogen may be sterile-filtered, but may not go through a 0.1 μ filter. A 0.2 μ filter is suggested, with positive pressure using a syringe and "button" filter. Vacuum filtration should not be used, since this will lead to breakdown of the molecule during the filtration.

Analysis Note

Protein determined by biuret

Disclaimer

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 5

1 of 5

Amphiphilic Copolymer Coatings via Plasma Polymerisation Process: Switching and Anti-Biofouling Characteristics.
Kumar V, et al.
Plasma Processes and Polymers, 8, 373-385 (2011)
L J Walsh et al.
Journal of dental research, 65(12), 1424-1426 (1986-12-01)
T6 is an antigen which is a highly specific marker for Langerhans cells. Previous studies have demonstrated that Interleukin-1 (IL-1) and an IL-1 inhibitor (ILS) modulate T6 expression (T6E) in explant culture. The present study examined the effects of IL-1
James S Dobson et al.
Toxins, 11(5) (2019-05-10)
The functional activities of Anguimorpha lizard venoms have received less attention compared to serpent lineages. Bite victims of varanid lizards often report persistent bleeding exceeding that expected for the mechanical damage of the bite. Research to date has identified the
Dwin Grashof et al.
Toxins, 12(2) (2020-02-06)
Envenomations are complex medical emergencies that can have a range of symptoms and sequelae. The only specific, scientifically-validated treatment for envenomation is antivenom administration, which is designed to alleviate venom effects. A paucity of efficacy testing exists for numerous antivenoms
Anastasia Koroleva et al.
Biofabrication, 4(1), 015001-015001 (2012-01-20)
Fabrication of three-dimensional (3D) fibrin scaffolds with tightly controllable pore sizes and interconnections has been investigated. The scaffolds were produced using a combination of two-photon polymerization (2PP) and micromolding techniques. Master structures were fabricated by 2PP and regenerated in fibrin

Articles

We will explore the technological advances that have contributed toward the progress of 3DP of tissue engineering scaffolds, current materials used to create 3DP scaffolds, and the challenges that remain.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service